预测老年头颈癌患者对顺铂的耐受性——为改善化放疗结局提供见解
本研究基于SENIOR数据库366例≥65岁接受顺铂单药根治性化放疗的头颈鳞癌患者,开发并比较了广义线性模型、支持向量机和随机森林模型预测累积顺铂剂量≥200 mg/m2的能力。195例(53%)达到该剂量,三种模型AUC分别为0.70、0.71和0.73,血红蛋白、CRP、eGFR和p16状态为重要预测特征。
要点
- 366例老年头颈鳞癌患者中195例(53%)达到累积顺铂剂量≥200 mg/m2。
- 广义线性模型中喉癌、p16阳性、较高血红蛋白、较高CRP和较高eGFR与达到≥200 mg/m2概率较高相关。
- 三种预测模型AUC为0.70-0.73,验证后可能辅助个体化治疗和共享决策。
核心结论
- 研究开发了预测模型,以支持临床医生识别能够在化放疗期间耐受累积顺铂≥200 mg/m2的老年头颈鳞癌患者。
- 这些模型经验证后可能改善老年头颈鳞癌患者的个体化治疗并增强共享决策。
研究设计与样本
- 来自SENIOR数据库(国际≥65岁头颈鳞癌成人队列)的366例接受顺铂单药根治性化放疗的患者被纳入分析。
- 训练并比较了广义线性模型(GLM)、支持向量机(SVM)和随机森林模型(RFM)预测累积顺铂剂量≥200 mg/m2的性能。
主要发现
- 195例(53%)患者达到累积顺铂剂量≥200 mg/m2。
- 在GLM中,喉癌(β=1.37,p=0.01)、肿瘤p16阳性(β=0.69,p=0.04)、较高血红蛋白水平(β=0.26,p=0.002)、升高C反应蛋白浓度(β=0.02,p=0.003)和增加估算肾小球滤过率(β=0.02,p=0.008)与达到≥200 mg/m2顺铂的较高概率相关。
- 血红蛋白、CRP、eGFR和p16状态是SVM和RFM中最重要的特征。
- GLM、SVM和RFM的AUC值分别为0.70(95%CI,0.67-0.73)、0.71(95%CI,0.68-0.73)和0.73(95%CI,0.71-0.75)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cumulative cisplatin doses of ≥ 200 mg/m2 improve survival in adults with head-and-neck squamous cell carcinoma (HNSCC) undergoing chemoradiation, but many older adults with HNSCC cannot receive this prognostically relevant dose due to toxicities. This study aims to develop predictive models to assess the likelihood of older adults with HNSCC receiving ≥ 200 mg/m2 cisplatin during chemoradiation. METHODS: 366 patients from the SENIOR database, an international cohort of adults ≥ 65 years with HNSCC, received definitive chemoradiation with single-agent cisplatin and were analyzed. A Generalized Linear Model (GLM), Support Vector Machine (SVM), and Random Forest Model (RFM) were trained and compared for their performance in predicting a cumulative cisplatin dose of ≥ 200 mg/m2. RESULTS: 195 (53 %) patients achieved a cumulative cisplatin dose of ≥ 200 mg/m2. In the GLM, laryngeal carcinoma (β = 1.37, p = 0.01), tumoral p16 positivity (β = 0.69, p = 0.04), higher hemoglobin levels (β = 0.26, p = 0.002), elevated C-reactive protein (CRP) concentration (β = 0.02, p = 0.003), and increased estimated glomerular filtration rate (eGFR) (β = 0.02, p = 0.008) were associated with a higher probability of reaching ≥ 200 mg/m2 cisplatin. Hemoglobin, CRP, eGFR, and p16 status constituted the most important features in the SVM and RFM. AUC values for the GLM, SVM, and RFM were 0.70 (95 % CI, 0.67-0.73), 0.71 (95 % CI, 0.68-0.73), and 0.73 (95 % CI, 0.71-0.75), respectively. CONCLUSIONS: We developed predictive models to support clinicians in identifying older adults with HNSCC capable of tolerating ≥ 200 mg/m2 cumulative cisplatin during chemoradiation. Once validated, these models could improve personalized treatments and enhance shared decision-making in older adults with HNSCC.
引用
- Rühle A, Weymann M, Behrens M, et al. Predicting cisplatin tolerability in older adults with head and neck cancer - Insights for improved chemoradiation outcomes. Radiother Oncol. 2024. PMID: 39725066. doi:10.1016/j.radonc.2024.110697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。